NeoDynamics

The company's lead product, the NeoNavia pulse biopsy system, has demonstrated improved precision and tissue yield compared to traditional core needle systems. Clinical studies show up to a ~299% larger sample size with the FlexiPulse needle versus standard side-notch core needles. The device enables accurate lesion targeting and high-quality tissue sampling from both breasts and lymph nodes with minimal trauma. It has been evaluated at leading clinics across Sweden, Germany, UK, and now launched commercially in the U.S., supported by multi-center clinical data including the PULSE study presented at major breast imaging conferences. No therapeutics are developed; focus remains on diagnostic accuracy.